InsidersTradesSigma
Follow the NovoCure Limited share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.1bn. The latest transaction was disclosed on 23 July 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: NICOLAS LEUPIN. The full history is openly available.
Analysts rate NovoCure Limited Buy (bullish), based on 7 analysts. Average price target: US$27.14.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
NovoCure Limited 是一家生物技术公司，致力于开发癌症患者的治疗方法。该公司在纳斯达克上市，股票代码为 NVCR。